Will This Efficacy Stumble Hurt Pfizer?
The Delta variant is putting up a fight.
Mindfully Curated
The Delta variant is putting up a fight.
With Disneyland Paris introducing a new paywall for access to expedited lines, it’s easy to see why Disneyland and Disney World may follow suit. Let’s go over reasons why it might not happen.
This fintech giant clearly has potential, but is it enough to help Square join a very select group of stocks?
COVID-19 is back in the news.
Real estate investment trusts are fertile ground for income investors who desire monthly dividends.
This iconic packaged food maker has been revamping its business. The pandemic has made the progress here harder to see.
Shares popped after the iconic casual clothing retailer released better-than-expected fiscal second-quarter results and raised its full-year guidance.
This sector was a big part of Thursday’s stock market decline.
Investors took profits from the sector after new pandemic fears surfaced.
These two simple ideas can help you apply the wisdom of one of the world’s greatest investors.
If you’ve started to live off of your nest egg, then this pair of reliable dividend payers could be a good, balanced fit for your portfolio.
The company is aiming to extend the recent momentum for its Switch console with an upgraded model coming later this year.
The local e-commerce upstart has made terrific progress in just over a year, and has plans to go bigger.
A $4.4 billion IPO, a crackdown by Chinese regulators, major fines, class-action lawsuits. Quite a week for the “Uber of China.”
Looking for stocks to buy as the world starts to come back to life? This trio is already benefiting.
Both have their advantages and disadvantages, but which one is right for you?
Shares of these Chinese fintech companies are suffering as regulators increase their oversight on Chinese companies listing on American stock exchanges.
Online dating is merging into real-life experiences.
The pandemic threw Chewy a bone, and the company ran with it.
ARK believes technology will boost the NPV of biopharmaceutical pipeline assets significantly during the next five to ten years.